
BioXcel Therapeutics is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy BioXcel Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BTAI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
BioXcel Therapeutics stock price (NASDAQ: BTAI)
Use our graph to track the performance of BTAI stocks over time.BioXcel Therapeutics shares at a glance
Latest market close | $18.86 |
---|---|
52-week range | $8.80 - $34.13 |
50-day moving average | $28.65 |
200-day moving average | $17.85 |
Wall St. target price | $55.18 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-5.40 |
Buy BioXcel Therapeutics stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy BioXcel Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioXcel Therapeutics price performance over time
Historical closes compared with the close of $18.86 from 2023-03-20
1 week (2023-03-14) | -7.23% |
---|---|
1 month (2023-02-21) | -40.80% |
3 months (2022-12-21) | -10.66% |
6 months (2022-09-21) | 56.64% |
1 year (2022-03-21) | 12.20% |
---|---|
2 years (2021-03-19) | -57.86% |
3 years (2020-03-20) | 9.27% |
5 years (2018-03-21) | 81.17% |
BioXcel Therapeutics financials
Revenue TTM | $375,000 |
---|---|
Gross profit TTM | $355,000 |
Return on assets TTM | -32.82% |
Return on equity TTM | -95.08% |
Profit margin | 0% |
Book value | $4.53 |
Market capitalisation | $549.3 million |
TTM: trailing 12 months
BioXcel Therapeutics share dividends
We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.
BioXcel Therapeutics share price volatility
Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $8.795 up to $34.125. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 1.1931. This would suggest that BioXcel Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
BioXcel Therapeutics overview
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics in the news
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
BioXcel Therapeutics, Inc. (NASDAQ:BTAI): When Will It Breakeven?
Frequently asked questions
What percentage of BioXcel Therapeutics is owned by insiders or institutions?Currently 32.222% of BioXcel Therapeutics shares are held by insiders and 55.553% by institutions. When does the fiscal year end for BioXcel Therapeutics?
BioXcel Therapeutics's fiscal year ends in December. Where is BioXcel Therapeutics based?
BioXcel Therapeutics's address is: 555 Long Wharf Drive, New Haven, CT, United States, 06511 What is BioXcel Therapeutics's ISIN number?
BioXcel Therapeutics's international securities identification number is: US09075P1057 What is BioXcel Therapeutics's CUSIP number?
BioXcel Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09075P105
More guides on Finder
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Ask an Expert